Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2024-05-10 Annual Report
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Press Release
Annual Report Classification · 95% confidence The document is a detailed announcement dated 10 May 2024 from Hester Biosciences Limited addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting. It includes the approval of audited standalone and consolidated financial results for the quarter and year ended 31 March 2024, along with the auditors' report with an unmodified opinion. The document also contains a press release with detailed financial highlights, profitability analysis, segment performance, and forward-looking statements. The presence of comprehensive financial data, including revenues, EBITDA, PAT, EPS, and segment-wise analysis, indicates this is a full financial report rather than a brief earnings release or a simple announcement. The document also mentions dividend recommendation and remuneration revision but the primary content is the audited financial results and the audit report. The length (over 12,000 characters) and detailed financial statements confirm this is not a mere announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K) or equivalent annual audited financial results filing. Given the Indian context and the detailed audited financial results for the full fiscal year, the best fitting category is Annual Report (10-K).
2024-05-10 English
Financial Result Updates
Regulatory Filings
2024-05-10 English
Dividend
Regulatory Filings
2024-05-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about an upcoming earnings conference call scheduled for May 10, 2024, following the announcement of financial results for the quarter and year ended March 31, 2024. It includes details for joining the call and contact information but does not contain any financial data or results itself. The document is short (2049 characters) and serves as an announcement rather than the transcript or report of the earnings call. Therefore, it fits the category of a Call Transcript (CT) announcement but since it is only an intimation of the call and not the transcript, the best classification is Regulatory Filings (RNS) as a general announcement under SEBI regulations.
2024-05-08 English
Board Meeting — HESTER BIOSCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the…
Regulatory Filings
2024-05-07 English
Board Meeting — Financial Results/Dividend
Board/Management Information Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board Meeting scheduled for 10 May 2024. It mentions that the Board will consider audited financial results for the quarter and year ended 31 March 2024 and possibly declare dividends. The document is an intimation or announcement of a future event (Board Meeting) rather than the actual financial results or dividend declaration. It is also very brief (1180 characters), indicating it is not a full report. According to the rules, such notices about board meetings fall under Board/Management Information (MANG).
2024-05-02 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.